首站-论文投稿智能助手
典型文献
Lynch syndrome pre-screening and comprehensive characterization in a multi-center large cohort of Chinese patients with colorectal cancer
文献摘要:
Objective: Lynch syndrome (LS) pre-screening methods remain under-investigated in colorectal cancers (CRCs) in Asia. Here, we aimed to systematically investigate LS pre-screening and comprehensively characterize LS CRCs. Methods: Microsatellite instability (MSI) and germline variants of DNA mismatch repair (MMR) genes were examined in 406 deficient MMR (dMMR) and 250 proficient MMR CRCs. The genetic differences between LS and sporadic CRCs were studied with whole exome sequencing analysis. Results: The incidence of dMMR in Chinese patients with CRCs was 13.8%. Consistency analysis between MMR immunohistochemistry (IHC) and MSI testing showed the kappa value was 0.758. With next-generation sequencing (NGS), germline variants were detected in 154 CRCs. Finally, 88 patients with CRC were identified as having LS by Sanger sequencing. Among them, we discovered 21 previously unreported pathogenic germline variants of MMR genes. Chinese patients with LS, compared with sporadic CRCs, tended to be early-onset, right-sided, early-stage and mucinous. Overall, the performance of MMR IHC and MSI testing for LS pre-screening was comparable: the area under the ROC curve for dMMR, MSI-H, and MSI-H/L was 0.725, 0.750, and 0.745, respectively. dMMR_MSI-H LS and sporadic CRCs showed substantial differences in somatic genetic characteristics, including different variant frequencies of APC, CREBBP, and KRAS, as well as different enriched pathways of VEGF, Notch, TGFβR, mTOR, ErbB, and Rac protein signal transduction. Conclusions: MMR IHC and MSI testing were effective methods for LS pre-screening. The revealed clinical and somatic genetic characteristics in LS CRCs may have the potential to improve the performance of LS pre-screening in combination with dMMR/MSI.
文献关键词:
作者姓名:
Yan Li;Lihong Fan;Jianming Zheng;Xiu Nie;Yu Sun;Qin Feng;Shenyi Lian;Wenqi Bai;Weijing Cai;Yanan Yang;Bo Su;Yanfeng Xi;Dongmei Lin
作者机构:
Department of Pathology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Department of Respiration Medicine,Shanghai Tenth People's Hospital,School of Medicine,Tongji University,Shanghai 200072,China;Department of Pathology,Changhai Hospital of Shanghai,Shanghai 200433,China;Department of Pathology,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Colorectal Surgery,Shanxi Cancer Hospital,Taiyuan 030013,China;Shanghai Tongshu Biotechnology Co.,Ltd,Shanghai 200120,China;Department of Biochemistry and Molecular Biology,Mayo Clinic,Rochester,MN 55905,USA;Central Laboratory,Shanghai Pulmonary Hospital,School of Medicine,Tongji University,Shanghai 200433,China;Department of Pathology,Shanxi Cancer Hospital,Taiyuan 030013,China
引用格式:
[1]Yan Li;Lihong Fan;Jianming Zheng;Xiu Nie;Yu Sun;Qin Feng;Shenyi Lian;Wenqi Bai;Weijing Cai;Yanan Yang;Bo Su;Yanfeng Xi;Dongmei Lin-.Lynch syndrome pre-screening and comprehensive characterization in a multi-center large cohort of Chinese patients with colorectal cancer)[J].癌症生物学与医学(英文版),2022(08):1235-1248
A类:
B类:
Lynch,syndrome,screening,characterization,multi,center,large,cohort,Chinese,patients,colorectal,Objective,LS,methods,remain,under,investigated,cancers,CRCs,Asia,Here,aimed,systematically,comprehensively,characterize,Methods,Microsatellite,instability,MSI,germline,variants,mismatch,repair,genes,were,examined,deficient,dMMR,proficient,genetic,differences,between,sporadic,studied,whole,exome,sequencing,analysis,Results,incidence,was,Consistency,immunohistochemistry,IHC,testing,showed,kappa,value,With,next,generation,NGS,detected,Finally,identified,having,by,Sanger,Among,them,discovered,previously,unreported,pathogenic,compared,tended,early,onset,right,sided,stage,mucinous,Overall,performance,comparable,area,curve,respectively,substantial,somatic,characteristics,including,different,frequencies,APC,CREBBP,KRAS,well,enriched,pathways,VEGF,Notch,TGF,mTOR,ErbB,Rac,protein,signal,transduction,Conclusions,effective,revealed,clinical,may,have,potential,improve,combination
AB值:
0.484556
相似文献
Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients
Panwen Tian;Xiaoyan Zhang;Sheng Yang;Yu Fang;Hongling Yuan;Wei Li;Honglin Zhu;Fangping Zhao;Jinlei Ding;Yunshu Zhu;Sizhen Wang;Guochen Sun;Hongbin Ni;Tonghui Ma;Ting Lei-Department of Respiratory and Critical Care Medicine,Lung Cancer Treatment Center,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China;Department of Translational Medicine,Genetron Health(Beijing)Technology,Co.Ltd.,Beijing 102206,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100005,China;Department of Thoracic Surgery,The Second Hospital of Dalian Medical University,Dalian,Liaoning 116023,China;Genetron Health(Beijing)Technology,Co.Ltd.,Beijing 102206,China;Department of Neurosurgery,The First Medical Center of PLA General Hospital,Beijing 100853,China;Department of Neurosurgery,Nanjing Drum Tower Hospital(Nanjing Gulou Yi Yuan),The Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,China
Sex disparity of lung cancer risk in non-smokers: a multicenter population-based prospective study based on China National Lung Cancer Screening Program
Wu Zheng;Tan Fengwei;Yang Zhuoyu;Wang Fei;Cao Wei;Qin Chao;Dong Xuesi;Zheng Yadi;Luo Zilin;Zhao Liang;Yu Yiwen;Xu Yongjie;Ren Jiansong;Shi Jufang;Chen Hongda;Li Jiang;Tang Wei;Shen Sipeng;Wu Ning;Chen Wanqing;Li Ni;He Jie-Office of Cancer Screening, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Key Laboratory of Cancer Data Science, Chinese Academy of Medical Sciences, Beijing 100021, China;Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;PET-CT Center, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu 211166, China;Department of Diagnostic Radiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII
Gui Yinli;Bai Wei;Xu Jian;Duan Xinwang;Zhan Feng;Zhao Chen;Jiang Zhenyu;Li Zhijun;Wu Lijun;Liu Shengyun;Yang Min;Wei Wei;Wang Ziqian;Zhao Jiuliang;Wang Qian;Leng Xiaomei;Tian Xinping;Li Mengtao;Zhao Yan;Zeng Xiaofeng;CSTAR co-authors-Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China;Department of Rheumatology, The People’s Hospital of Zhengzhou, Zhengzhou, Henan 450003, China;Department of Rheumatology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, China;Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China;Department of Rheumatology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311, China;Department of Rheumatology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China;Department of Rheumatology, The Bethune First Hospital of Jilin University, Changchun, Jilin 130021, China;Department of Rheumatology, The Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China;Department of Rheumatology, The People’s Hospital of Xinjiang Autonomous Region, Urumqi, Xinjiang 830001, China;Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China;Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China;Department of Rheumatology, Tianjin Medical University General Hospital, Tianjin 300052, China
Predictors of pathologic complete response in patients with residual flat mucosal lesions after neoadjuvant chemoradiotherapy for locally advanced rectal cancer
Changlong Li;Zhen Guan;Yi Zhao;Tingting Sun;Zhongwu Li;Weihu Wang;Zhexuan Li;Lin Wang;Aiwen Wu-Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Gastrointestinal Cancer Center,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Radiology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Pathology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Radiation Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Cancer Epidemiology,Peking University Cancer Hospital&Institute,Beijing 100142,China
A multi-center, open-label, randomized, parallel-controlled phase Ⅱ study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera?) in patients with CD20-positive B-cell non-Hodgkin lymphoma
Xiaohong Han;Mingzhi Zhang;Huaqing Wang;Qingyuan Zhang;Wei Li;Miaowang Hao;Yuhuan Gao;Jie Jin;Hanyun Ren;Yun Tang;Xiaonan Hong;Xiaoyan Ke;Hang Su;Lin Gui;Jianmin Luo;Liangzhi Xie;Wenlin Gai;Yuankai Shi-Clinical Pharmacology Research Center,Peking Union Medical College Hospital,State Key Laboratory of Complex Severe and Rare Diseases,NMPA Key Laboratory for Clinical Research and Evaluation of Drug,Beijing Key Laboratory of Clinical PK&PD Investigation for Innovative Drugs,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China;Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Department of Medical Oncology,Tianjin People's Hospital,Tianjin 300121,China;Department of Medical Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China;Oncology Department of Cancer Center,the First Hospital of Jilin University,Changchun 130021,China;Department of Hematology,Tangdu Hospital,Air Force Medical University,Xi'an 710038,China;Department of Hematology,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Hematology,the First Affiliated Hospital of Zhejiang University,Hangzhou 310003,China;Department of Hematology,Peking University First Hospital,Beijing 100034,China;Department of Hematology,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Medical Oncology,Fudan University Shanghai Cancer Center,Shanghai 200032,China;Department of Hematology,Peking University Third Hospital,Beijing 100191,China;Department of Lymphoma,the Fifth Medical Center of PLA General Hospital,Beijing 100071,China;Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,Beijing 100021,China;Department of Hematology,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China;Beijing Engineering Research Center of Protein and Antibody,Sinocelltech Ltd.,Beijing 100176,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。